The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 728-740

  Noël, Laura A ^a   Arts, Florence A ^a   Montano Almendras, Carmen P ^a   Cox, Luk ^b,c   Gielen, Olga ^b,c   Toffalini, Federica ^a   Marbehant, Catherine Y ^a   Cools, Jan ^b,c   Demoulin, Jean Baptiste ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Chronic eosinophilic leukemia; PDGFRA; PTPN11; SHP2; STAT5

Indexed keywords

LIGAND; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; TYROSINE; TYROSINE 720; UNCLASSIFIED DRUG; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN BINDING; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; MUTATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; ONCOGENE; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; CELL CULTURE; CELL LINE; GENETICS; METABOLISM;

MUS;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84899474059     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.02.003     Document Type: Article

References (59)

1. Ali S., Nouhi Z., Chughtai N. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J.Biol. Chem. 2003, 278:52021-52031.
2. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008, 22:1276-1312.
3. Araki T., Nawa H., Neel B.G. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J.Biol. Chem. 2003, 278:41677-41684.
4. Bazenet C.E., Gelderloos J.A., Kazlauskas A. Phosphorylation of tyrosine 720 in the platelet-derived growth factor alpha receptor is required for binding of Grb2 and SHP-2 but not for activation of Ras or cell proliferation. Mol. Cell Biol 1996, 16:6926-6936.
5. Bennett A.M., Tang T.L., Sugimoto S., Walsh C.T., Neel B.G. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc. Natl. Acad. Sci. U S A 1994, 91:7335-7339.
6. Buitenhuis M., Verhagen L.P., Cools J., Coffer P.J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res. 2007, 67:3759-3766.
7. Chan G., Kalaitzidis D., Neel B.G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008, 27:179-192.
8. Chen J., Yu W.M., Bunting K.D., Qu C.K. A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival. Oncogene 2004, 23:3659-3669.
9. Chen Y., Wen R., Yang S., Schuman J., Zhang E.E., Yi T., Feng G.S., Wang D. Identification of Shp-2 as a Stat5A phosphatase. J.Biol. Chem. 2003, 278:16520-16527.
10. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N.Engl. J. Med. 2003, 348:1201-1214.
11. Cools J., Stover E.H., Boulton C.L., Gotlib J., Legare R.D., Amaral S.M., Curley D.P., Duclos N., Rowan R., Kutok J.L., Lee B.H., Williams I.R., Coutre S.E., Stone R.M., DeAngelo D.J., Marynen P., Manley P.W., Meyer T., Fabbro D., Neuberg D., Weisberg E., Griffin J.D., Gilliland D.G. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003, 3:459-469.
12. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., Shiraga S., Bainbridge T., Morich J., Heinrich M.C. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and invitro sensitivity to imatinib. J.Clin. Oncol. 2005, 23:5357-5364.
13. Dance M., Montagner A., Salles J.P., Yart A., Raynal P. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal 2008, 20:453-459.
14. Demoulin J.B., Uyttenhove C., Lejeune D., Mui A., Groner B., Renauld J.C. STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res. 2000, 60:3971-3977.
15. Dewaele B., Wasag B., Cools J., Sciot R., Prenen H., Vandenberghe P., Wozniak A., Schoffski P., Marynen P., Debiec-Rychter M. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin. Cancer Res. 2008, 14:5749-5758.
16. Elling C., Erben P., Walz C., Frickenhaus M., Schemionek M., Stehling M., Serve H., Cross N.C., Hochhaus A., Hofmann W.K., Berdel W.E., Muller-Tidow C., Reiter A., Koschmieder S. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011, 117:2935-2943.
17. Ezeokonkwo, C., Zhelkovsky, A., Lee, R., Bohm, A., Moore, C.L., A flexible linker region in Fip1 is needed for efficient mRNA polyadenylation. Rna 17, 652-664.
18. Fambrough D., McClure K., Kazlauskas A., Lander E.S. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 1999, 97:727-741.
19. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002, 359:1577-1578.
20. Goss V.L., Lee K.A., Moritz A., Nardone J., Spek E.J., MacNeill J., Rush J., Comb M.J., Polakiewicz R.D. A common phosphotyrosine signature for the Bcr-Abl kinase. Blood 2006, 107:4888-4897.
21. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., Fletcher J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
22. Heldin C.H., Östman A., Rönnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1998, 1378:F79-F113.
23. Huss S., Wardelmann E., Goltz D., Binot E., Hartmann W., Merkelbach-Bruse S., Buttner R., Schildhaus H.U. Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization. Histopathology 2012, 61:59-68.
24. Kallin A., Demoulin J.B., Nishida K., Hirano T., Ronnstrand L., Heldin C.H. Gab1 contributes to cytoskeletal reorganization and chemotaxis in response to platelet-derived growth factor. J.Biol. Chem. 2004, 279:17897-17904.
25. Leevers S.J., Marshall C.J. Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. Embo J. 1992, 11:569-574.
26. Leischner H., Albers C., Grundler R., Razumovskaya E., Spiekermann K., Bohlander S., Ronnstrand L., Gotze K., Peschel C., Duyster J. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML. Blood 2012, 119:4026-4033.
27. Lierman E., Michaux L., Beullens E., Pierre P., Marynen P., Cools J., Vandenberghe P. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
28. Liu X., Qu C.K. Protein tyrosine phosphatase SHP-2 (PTPN11) in Hematopoiesis and leukemogenesis. J.Signal Transduction 2011, 2011:195239.
29. Louahed J., Grasso L., De Smet C., Van Roost E., Wildmann C., Nicolaides N.C., Levitt R.C., Renauld J.C. Interleukin-9-induced expression of M-Ras/R-Ras3 oncogene in T-helper clones. Blood 1999, 94:1701-1710.
30. Lu W., Gong D., Bar-Sagi D., Cole P.A. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell 2001, 8:759-769.
31. Mali R.S., Ma P., Zeng L.F., Martin H., Ramdas B., He Y., Sims E., Nabinger S., Ghosh J., Sharma N., Munugalavadla V., Chatterjee A., Li S., Sandusky G., Craig A.W., Bunting K.D., Feng G.S., Chan R.J., Zhang Z.Y., Kapur R. Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood 2012, 120:2669-2678.
32. Martinelli S., Torreri P., Tinti M., Stella L., Bocchinfuso G., Flex E., Grottesi A., Ceccarini M., Palleschi A., Cesareni G., Castagnoli L., Petrucci T.C., Gelb B.D., Tartaglia M. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. Hum. Mol. Genet. 2008, 17:2018-2029.
33. Medves S., Duhoux F.P., Ferrant A., Toffalini F., Ameye G., Libouton J.M., Poirel H.A., Demoulin J.B. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Leukemia 2010, 24:1052-1055.
34. Medves S., Noel L.A., Montano-Almendras C.P., Albu R.I., Schoemans H., Constantinescu S.N., Demoulin J.B. Multiple oligomerization domains of KANK1-PDGFRB are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Haematologica 2011, 96:1406-1414.
35. Metzgeroth G., Walz C., Erben P., Popp H., Schmitt-Graeff A., Haferlach C., Fabarius A., Schnittger S., Grimwade D., Cross N.C., Hehlmann R., Hochhaus A., Reiter A. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br. J. Haematol. 2008, 143:707-715.
36. Miyake S., Mullane-Robinson K.P., Lill N.L., Douillard P., Band H. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J.Biol. Chem. 1999, 274:16619-16628.
37. Montano-Almendras C.P., Essaghir A., Schoemans H., Varis I., Noel L.A., Velghe A.I., Latinne D., Knoops L., Demoulin J.B. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor proliferation and differentiation into eosinophils: role of nuclear factor [kappa]B. Haematologica 2012, 97:1064-1072.
38. Mulligan G., Lichter D.I., Di Bacco A., Blakemore S.J., Berger A., Koenig E., Bernard H., Trepicchio W., Li B., Neuwirth R., Chattopadhyay N., Bolen J.B., Dorner A.J., van de Velde H., Ricci D., Jagannath S., Berenson J.R., Richardson P.G., Stadtmauer E.A., Orlowski R.Z., Lonial S., Anderson K.C., Sonneveld P., San Miguel J.F., Esseltine D.L., Schu M. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 2013, 123:632-639.
39. Nabinger S.C., Li X.J., Ramdas B., He Y., Zhang X., Zeng L., Richine B., Bowling J.D., Fukuda S., Goenka S., Liu Z., Feng G.S., Yu M., Sandusky G.E., Boswell H.S., Zhang Z.Y., Kapur R., Chan R.J. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease invivo. Leukemia 2013, 27:398-408.
40. Neel B.G., Gu H., Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 2003, 28:284-293.
41. Pluskey S., Wandless T.J., Walsh C.T., Shoelson S.E. Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. J.Biol. Chem. 1995, 270:2897-2900.
42. Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P., Druker B.J., Naramura M., Band V., Band H. Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation. J.Biol. Chem. 2007, 282:29336-29347.
43. Ronnstrand L., Arvidsson A.K., Kallin A., Rorsman C., Hellman U., Engstrom U., Wernstedt C., Heldin C.H. SHP-2 binds to Tyr763 and Tyr1009 in the PDGF beta-receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and chemotaxis. Oncogene 1999, 18:3696-3702.
44. Rupp E., Siegbahn A., Ronnstrand L., Wernstedt C., Claesson-Welsh L., Heldin C.H. A unique autophosphorylation site in the platelet-derived growth factor alpha receptor from a heterodimeric receptor complex. Eur. J. Biochem./FEBS 1994, 225:29-41.
45. Schwaller J., Frantsve J., Aster J., Williams I.R., Tomasson M.H., Ross T.S., Peeters P., Van Rompaey L., Van Etten R.A., Ilaria R., Marynen P., Gilliland D.G. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. Embo J. 1998, 17:5321-5333.
46. Stover E.H., Chen J., Folens C., Lee B.H., Mentens N., Marynen P., Williams I.R., Gilliland D.G., Cools J. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc. Natl. Acad. Sci. U S A 2006, 103:8078-8083.
47. Sun J., Pedersen M., Ronnstrand L. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. J.Biol. Chem. 2009, 284:11039-11047.
48. Sweeney M.C., Wavreille A.S., Park J., Butchar J.P., Tridandapani S., Pei D. Decoding protein-protein interactions through combinatorial chemistry: sequence specificity of SHP-1, SHP-2, and SHIP SH2 domains. Biochemistry 2005, 44:14932-14947.
49. Tallquist M.D., French W.J., Soriano P. Additive effects of PDGF receptor beta signaling pathways in vascular smooth muscle cell development. PLoS Biol. 2003, 1:E52.
50. Toffalini F., Demoulin J.B. New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010, 116:2429-2437.
51. Toffalini F., Hellberg C., Demoulin J.B. Critical role of the platelet-derived growth factor receptor (PDGFR)-beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. J.Biol. Chem. 2010, 285:12268-12278.
52. Toffalini F., Kallin A., Vandenberghe P., Pierre P., Michaux L., Cools J., Demoulin J.B. The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation. Haematologica 2009, 94:1085-1093.
53. Tomasson M.H., Sternberg D.W., Williams I.R., Carroll M., Cain D., Aster J.C., Ilaria R.L., Van Etten R.A., Gilliland D.G. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J.Clin. Invest. 2000, 105:423-432.
54. Valgeirsdottir S., Paukku K., Silvennoinen O., Heldin C.H., Claesson-Welsh L. Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene 1998, 16:505-515.
55. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., Harris N.L., Le Beau M.M., Hellstrom-Lindberg E., Tefferi A., Bloomfield C.D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
56. Velghe A.I., Van Cauwenberghe S., Polyansky A.A., Chand D., Montano-Almendras C.P., Charni S., Hallberg B., Essaghir A., Demoulin J.B. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene 2013, 10.1038/onc.2013.218.
57. Walter A.O., Peng Z.Y., Cartwright C.A. The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene 1999, 18:1911-1920.
58. Xu D., Qu C.K. Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. A J. Virtual Libr. 2008, 13:4925-4932.
59. Zhang S.Q., Yang W., Kontaridis M.I., Bivona T.G., Wen G., Araki T., Luo J., Thompson J.A., Schraven B.L., Philips M.R., Neel B.G. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 2004, 13:341-355.